



# KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

Our Company was incorporated as 'Jagjit Singh and Sons Private Limited', a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, Maharashtra at Mumbai on July 26, 1973. Our Company changed the location of its registered office from the State of Maharashtra to the erstwhile State of Andhra Pradesh, pursuant to an order dated January 29, 2003 by the Company Law Board, Western Region Bench, Mumbai ("Order") and the registration of the Order vide certificate of registration dated February 21, 2003 by the Registrar of Companies, Andhra Pradesh and Telangana (then the Registrar of Companies, Andhra Pradesh) ("RoC"). Subsequently, the name of our Company was changed to 'Krishna Institute of Medical Sciences Private Limited', pursuant to a letter of approval from the Central Government dated January 2, 2004 and a fresh certificate of incorporation issued by the RoC on January 2, 2004. Further, pursuant to the conversion of our Company to a public limited company, our name was changed to 'Krishna Institute of Medical Sciences Limited' and the RoC issued a fresh certificate of incorporation on January 29, 2004. For further details, see "History and Certain Corporate Matters" on page 198 of the Red Herring Prospectus ("RHP") dated June 9, 2021. Registered and Corporate Office: D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana - 500 003, India; Tel: +91 40 4418 6000; Website: www.kimshospitals.com; Contact Person: Umashankar Mantha, Company Secretary and Compliance Officer; E-mail: cs@kimshospitals.com; Corporate Identity Number: U65101TG1973PLC040558

**OUR PROMOTERS: DR. BHASKARA RAO BOLLINENI, RAJYASRI BOLLINENI, DR. ABHINAY BOLLINENI, ADWIK BOLLINENI AND BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED**

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹10 EACH ("EQUITY SHARES") OF KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED ("COMPANY" OR "ISSUER") FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) (THE "OFFER PRICE") AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER") COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES AGGREGATING UP TO ₹ 2,000.00 MILLION (THE "FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 23,560,538 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION (THE "OFFER FOR SALE"), COMPRISING UP TO 16,003,615 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY GENERAL ATLANTIC SINGAPORE KH PTE. LTD (THE "INVESTOR SELLING SHAREHOLDER"), UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY DR. BHASKARA RAO BOLLINENI, UP TO 775,933 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY RAJYASRI BOLLINENI, UP TO 387,966 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY BOLLINENI RAMANAIAH MEMORIAL HOSPITALS PRIVATE LIMITED (COLLECTIVELY, THE "PROMOTER SELLING SHAREHOLDERS"), 6,005,058 EQUITY SHARES AGGREGATING UP TO ₹ [●] MILLION BY PERSONS REFERRED TO IN ANNEXURE A (REFERRED TO AS THE "OTHER SELLING SHAREHOLDERS", TOGETHER WITH THE INVESTOR SELLING SHAREHOLDER AND PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS", AND SUCH EQUITY SHARES THE "OFFERED SHARES"). THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES, AGGREGATING UP TO ₹ 200.00 MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES (THE "EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS "NET OFFER". THE OFFER AND NET OFFER SHALL CONSTITUTE [●]% AND [●]%, RESPECTIVELY, OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

**QIB Portion: Not Less than 75% of the Offer | Retail Portion: Not more than 10% of the Offer | Non-Institutional Portion: Not more than 15% of the Offer | Employee Reservation Portion: Up to [●] Equity Shares aggregating up to ₹ 200 million**

**Price Band: ₹ 815 to ₹ 825 per Equity Share of face value of ₹10 each.**

**A discount of ₹ 40 per Equity Share is being offered to Eligible Employees Bidding in the Employee Reservation Portion**

**The Floor Price is 81.50 times the face value of the Equity Shares and the Cap Price is 82.50 times the face value of the Equity Shares.**

**Bids can be made for a minimum of 18 Equity Shares and in multiples of 18 Equity Shares thereafter.**

**ASBA\***

**Simple, Safe, Smart way of Application!!!**

\*Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, For further details, check section on ASBA below.

**Mandatory in public issues. No cheque will be accepted.**



**UPI-Now available in ASBA for Retail Individual Bidders ("RIBs") applying through Registered Brokers, DPs and RTAs. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.**

**Investors are required to ensure that the bank account used for bidding is linked to their PAN.**

\*ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by RIBs. For details on the ASBA and UPI process, please refer to the details given in ASBA Form and abridged prospectus and also please refer to the section "Offer Procedure" beginning on page 381 of the RHP. The process is also available on the website of Association of Investment Bankers of India "AIBI", BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE"), and together with BSE, the "Stock Exchanges") and in the General Information Document. ASBA Forms can be downloaded from the websites of the Stock Exchanges and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of SEBI at www.sebi.gov.in. For list of banks supporting UPI, please refer to the link; www.sebi.gov.in. RIBs Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40) and (https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43) respectively, as updated from time to time. HDFC Bank Limited has been appointed as Sponsor Bank for the Offer. For issue related queries, investors may contact: the Book Running Lead Managers ("BRLMs") and Registrar to the Offer on their respective email IDs as mentioned below. For UPI related queries, investors can contact NPCI at the toll free number: 1800 1201 740 and Mail ID: ipo.upi@npci.org.in.

## Risks to Investors

- Average cost of acquisition of Equity Shares held by the Selling Shareholders ranges from ₹ 5.15 per Equity Share to ₹ 360.00 per Equity Share and Offer Price at upper end of the Price Band is ₹ 825.**
- The Price/Earnings ratio based on diluted EPS on a restated consolidated basis for Fiscal 2021 for the Issuer at the upper end of the Price Band is 31.23x. For our peer group, three companies have negative earnings per share for Fiscal 2021 and accordingly the Price/Earnings ratio for them is not applicable. Only one company in the peer group has positive earnings per share and accordingly the Price/Earnings ratio for the respective company is 101.39x for Fiscal 2020.**
- The four book running lead managers ("BRLMs") associated with the Offer have handled 29 public issues in the past three years, out of which 10 issues closed below the issue price on listing date.**
- Weighted Average Return on Net Worth for Fiscals 2021, 2020, 2019 is 16.82%.**

## BASIS FOR OFFER PRICE

The Offer Price will be determined by our Board or the IPO Committee, as applicable, in consultation with the BRLMs, on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process and on the basis of qualitative and quantitative factors as described below. The face value of the Equity Shares is ₹10 and the Offer Price is 81.50 times the face value at the lower end of the Price Band and 82.50 times the face value at the higher end of the Price Band. Investors should also refer to "Risk Factors", "Our Business" and "Financial Information" on pages 28, 165 and 233 of the RHP, respectively, to have an informed view before making an investment decision.

**Qualitative Factors:** Some of the qualitative factors which form the basis for the Offer Price are: 1. Regional leadership through delivering clinical excellence and affordable healthcare. 2. Ability to attract, train and retain high quality doctors, consultants and medical support staff. 3. Track record of strong operational and financial performance. 4. Well positioned to consolidate in India's large, unorganised yet rapidly growing and underserved affordable healthcare market. 5. Disciplined approach to acquisitions resulting in successful inorganic growth. 6. Experienced senior management team with strong institutional shareholder support. For further information, see "Our Business - Competitive Strengths" on page 167 of the RHP.

**Quantitative Factors:** Some of the information presented below relating to our Company is derived from the Restated Financial Statements. For further information, see "Financial Information" on page 233 of the RHP. Some of the quantitative factors which may form the basis for computing the Offer Price are as follows:

### 1. Basic and Diluted Earnings per Equity Share

Fiscal ended	Basic EPS (₹)	Diluted EPS (₹)	Weight
March 31, 2021	26.87	26.42	3
March 31, 2020	16.00	15.87	2
March 31, 2019	(6.91)	(6.91)	1
Weighted Average	17.62	17.35	

**Note:** (1) Basic and diluted earnings per Equity Share are computed in accordance with Ind AS 33 'Earnings per Share' prescribed under Section 133 of the Companies Act, 2013 read with rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 (as amended) read with the requirement of SEBI ICDR Regulations. (2) Basic EPS = Restated profit / (loss) attributable to equity shareholders of the Company divided by weighted average number of equity shares outstanding during the year - basic. (3) Diluted EPS = Restated profit / (loss) attributable to equity shareholders of the Company divided by weighted average number of equity shares outstanding during the year - diluted. (4) Weighted average number of Equity Shares is the number of shares outstanding at the beginning of the year adjusted by the number of shares issued during the year multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the year. (5) Weighted Average basic and diluted EPS is a product of basic and diluted EPS and respective assigned weight, dividing the resultant by total aggregate weight. Weights applied have been determined by the management of the Company.

### 2. Price/Earning ("P/E") Ratio in relation to the Price Band of ₹ 815 to ₹ 825 per Equity Share:

Particulars	P/E at Floor Price (no. of times)	P/E at Cap Price (no. of times)	Industry P/E ratio*	Particulars	P/E
Based on basic EPS	30.33	30.70	Highest		101.39
Based on diluted EPS	30.85	31.23	Lowest		101.39
			Average		101.39

\*Source: The highest, lowest and average Industry P/E shown above is based on the industry peer set provided below under "- Comparison with Listed Industry Peers" on page 109 of the RHP.

### 3. Return on Net Worth ("RoNW")

Fiscal ended	RoNW (%)	Weight
March 31, 2021	23.30	3
March 31, 2020	19.93	2
March 31, 2019	(8.84)	1
Weighted Average	16.82	

**Note:** (1) Return on net worth - we have calculated based on the profit after tax - attributable to owners of the Company divided by total equity attributable to owners of the Company. (2) Our return on net worth reflect our results of operations after making certain adjustments. For more information, see "Other Financial Information" on page 311 of the RHP.

### 4. Net Asset Value ("NAV")

Net Asset Value per Equity Share	(₹)
As on March 31, 2021	115.36
After the Offer	
- At the Floor price	132.87
- At the Cap price	132.92
Offer Price	[●]

**Notes:** (1) Net asset value per equity share (₹) = total equity attributable to owners of the Company divided weighted average number of equity shares outstanding during the year - basic. (2) Our net asset value reflect our results of operations after making certain adjustments. For more information, see "Other Financial Information" on page 311 of the RHP.

### 5. Comparison with Listed Industry Peers

Following is the comparison with our peer group companies listed in India and in the same line of business as our Company:

Name of the company	Consolidated	Face value (₹ per share)	Closing price on June 7, 2021	Total income for Fiscal 2021/2020 (in ₹ million)*	EPS (₹) Basic Diluted <sup>(i)</sup>	NAV <sup>(ii)</sup> (₹ per share)	P/E <sup>(iii)</sup>	RoNW <sup>(iv)</sup> (%)
Our Company(5)	Consolidated	10	NA	13,401.02*	26.87* 26.42*	115.36	[●]	23.30%
<b>PEER GROUP#</b>								
Apollo Hospitals Enterprise Limited	Consolidated	5	3,315.30	112,468.00	32.70 32.70	240.10	101.39	12.91
Fortis Healthcare Limited	Consolidated	10	236.25	40,766.80	(1.45) (1.45)	88.98	NA	1.37
Narayana Hrudayalaya Limited	Consolidated	10	481.15	26,105.22	(0.70) (0.70)	54.85	NA	10.48
Max Healthcare Institute Limited	Consolidated	10	244.15	26,194.10	(1.59) (1.59)	57.34	NA	9.66

**Notes:** \*Based on Restated Financial Statements as on and year ended March 31, 2021 # Financial Information of Fortis Healthcare Limited, Narayana Hrudayalaya Limited and Max Healthcare Institute Limited has been sourced from the financial statements for the year ended March 31, 2021 and financial information of Apollo Hospitals Enterprise Limited has been sourced from the annual report for the year ended March 31, 2020.

(1) Diluted EPS refers to the Diluted EPS sourced from the financial statements of the respective peer group companies for the year ended March 31, 2021 except for Apollo Hospitals Enterprise Limited for which the information is sourced from annual report for the closing outstanding number of equity shares as on March 31, 2021 except for Apollo Hospitals Enterprise Limited for which the information is sourced from annual report for the year ended March 31, 2020. (3) P/E Ratio has been computed based on the closing market price of equity shares on NSE on June 7, 2021, divided by the Diluted EPS provided under Note 1 above. (4) RoNW is computed as net profit after tax (including profit attributable to non-controlling interest) divided by closing net worth. Closing net worth has been computed as sum of paid-up share capital and other equity as on March 31, 2021 except for Apollo Hospitals Enterprise Limited for which the information is sourced from annual report for the year ended March 31, 2020. (5) Net asset value (basic), return on net worth for our Company are non-GAAP measures. These non-GAAP measures are not meant to be considered in isolation or as a substitute for our profit before tax expense, profit after tax or any other financial measure prepared in accordance with Ind AS. The non-GAAP measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure. For information on how these non-GAAP measures are calculated and a reconciliation to our most directly comparable GAAP measures, see "Management's Discussion and Analysis of Financial Condition and Results of Operations-Our Results of Operations-Non-GAAP Financial Measures" on page 342 of the RHP. Please see, "Risk Factors - This Red Herring Prospectus contains certain Non-GAAP measures financial and operational measures related to our operations and financial performance that may vary from any standard methodology that is applicable across the industry." on page 31 of the RHP.

The trading price of the Equity Shares could decline due to the factors mentioned in the section titled "Risk Factors" on page 28 of the RHP and any other factors that may arise in the future and you may lose all or part of your investments.

The Offer Price of ₹ [●] has been determined by our Board or the IPO Committee, as applicable, in consultation with the BRLMs, on the basis of the demand from investors for the Equity Shares through the Book Building process. Our Board or the IPO Committee, as applicable, in consultation with the BRLMs, are justified of the Offer Price in view of the above qualitative and quantitative parameters. Investors should read the abovementioned information along with "Risk Factors", "Our Business" and "Financial Information" on pages 28, 165 and 233 of the RHP, respectively, to have a more informed view. The trading price of the Equity Shares could decline due to the factors mentioned in "Risk Factors" or any other factors that may arise in the future and you may lose all or part of your investments.

**FOR FURTHER DETAILS, SEE "BASIS FOR OFFER PRICE" BEGINNING ON PAGE 108 OF THE RHP.**

**BID/OFFER PROGRAMME**

**OPENS ON: WEDNESDAY, JUNE 16, 2021\***

**CLOSES ON: FRIDAY, JUNE 18, 2021\*\***

\*Our Board or the IPO Committee, as applicable, may in consultation with the Book Running Lead Managers, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/Offer Period shall be one Working Day prior to the Bid/Offer Opening Date.

\*\*UPI mandate end time and date shall be at 12:00 pm on Monday, June 21, 2021.

In case of any revision in the Price Band, the Bid/Offer Period will be extended by at least three additional Working Days after revision of the Price Band, subject to the Bid/Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, in consultation with the Book Running Lead Managers, may, for reasons to be recorded in writing, extend the Bid/Offer Period for a minimum of three Working Days, subject to the Bid/Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release, and also by indicating the change on the respective websites of the Book Running Lead Managers and at the terminals of the member of the Syndicate and by an intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process, in compliance with Regulation 6(2) of the SEBI ICDR Regulations, wherein not less than 75% of the Net Offer will be Allotted on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Board or the IPO Committee, as applicable, may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"). Further, 5% of the Net QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs (excluding the Anchor Investor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. If at least 75% of the Offer cannot be Allotted to QIBs, then the entire application money will be refunded forthwith. Further, not more than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not more than 10% of the Net Offer shall be available for allocation to RIBs, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, Equity Shares may be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RIBs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see "Offer Procedure" on page 381 of the RHP.

**Bidders/Applicants should ensure that DP ID, PAN and the Client ID and UPI ID (if applicable, in case RIBs) are correctly filled in the Bid cum Application Form. The DP ID, PAN and Client ID provided in the Bid cum Application Form should match with the DP ID, PAN, Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Bidders/Applicants should note that on the basis of the PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorized the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for giving Allotment Advice or unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants' sole risk.**

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
 <b>Kotak Mahindra Capital Company Limited</b> 27 BKC, 1st Floor, Plot No. C – 27, 'G' Block, Bandra Kurla Complex, Bandra (East) Mumbai 400 051, Maharashtra, India Tel: +91 22 4336 0000 E-mail: kims.ipo@kotak.com Website: www.investmentbank.kotak.com Investor Grievance ID: kmccredressal @kotak.com Contact Person: Ganesh Rane SEBI Registration Number: INM000008704	 <b>Axis Capital Limited</b> 1st Floor, Axis House, C-2, Wadia International Centre, P.B. Marg, Worli, Mumbai 400 025 Maharashtra, India Tel: +91 22 4325 2183 E-mail: kims.ipo@axiscap.in Website: www.axiscapital.co.in Investor Grievance ID: complaints@axiscap.in Contact Person: Ankit Bhatia SEBI Registration Number: INM000012029	 <b>Credit Suisse Securities (India) Private Limited</b> Ceejay House, 10th Floor, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai 400 018 Maharashtra, India. Tel: +91 22 6777 3777 E-mail: list.kimsipo@credit-suisse.com Website: https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html Investor Grievance ID: list.icgellmerbnkg@credit-suisse.com Contact Person: Chunky Shah SEBI Registration Number: INM000011161	 <b>IIFL Securities Limited</b> 10th Floor, IIFL Centre, Kamala City, Senapati Bapat Marg, Lower Parel (West), Mumbai 400 013, Maharashtra, India Tel: +91 22 4646 4600 E-mail: kims.ipo@iiflcap.com Website: www.iiflcap.com Investor Grievance ID: ig_ib@iiflcap.com Contact person: Shirish Chikalge/Keyur Ladhawala SEBI Registration Number: INM000010940	 <b>Link Intime India Private Limited</b> C-101, 247 Park L B S Marg, Vikhroli (West) Mumbai 400 083, Maharashtra, India Tel: +91 22 4918 6200 E-mail: kims.ipo@linkintime.com Website: www.linkintime.co.in Investor grievance ID: kims.ipo@linkintime.com Contact Person: Shanti Gopalakrishnan SEBI Registration Number: INR000004058	<b>Umashankar Mantha</b> D. No. 1-8-31/1, Minister's Road, Secunderabad - 3, Telangana - 500 003, India. <b>Telephone:</b> +91 40 4418 6433 <b>E-mail:</b> cs@kimshospitals.com  Investors may contact the Company Secretary and Compliance Officer or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances including non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of funds by electronic mode, etc.

**AVAILABILITY OF RHP:** Investors are advised to refer to the RHP and the Risk Factors, contained therein before applying in the Offer. Full copy of the RHP is available on website of SEBI at www.sebi.gov.in, websites of the BRLMs i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively and websites of BSE and NSE i.e. www.bseindia.com and www.nseindia.com, respectively.

**AVAILABILITY OF BID CUM APPLICATION FORMS:** Bid cum Application Forms can be obtained from the Registered Office of **KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED**, Tel: +91 40 4418 6000; Book Running Lead Managers: **Kotak Mahindra Capital Company Limited**, Tel: +91 22 4336 0000, **Axis Capital Limited**, Tel: +91 22 4325 2183, **Credit Suisse Securities (India) Private Limited**, Tel: +91 22 6777 3777 and **IIFL Securities Limited**, Tel: +91 22 4646 4600 and **Syndicate Members: Kotak Securities Limited**, Tel: +91 22 6218 5470 and at the select locations of the Sub-syndicate Members, SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

**Sub-Syndicate Members:** Almondz Global Securities Limited, Amrapali Capital & Finance Services Limited, Anand Ratni Share & Stock Brokers Limited, Anand Share Consultancy, ANS Pvt. Limited, Ashwani Dandia & Co., Axis Securities Limited, Bonanza Portfolio Limited, Centrum Broking Limited, Dalal & Broacha Stock Broking Pvt. Limited, Edelweiss Broking Limited, G Raj & Co. (Consultants) Limited, Globe Capital Market Limited, Jhaveri Securities, JM Financial Services Limited, Jobanputra Fiscal Services Private Limited, Kalpataru Multiplier Limited, LKP Securities Limited, Marwadi Shares & Finance, Motilal Oswal Financial Services Limited, Motilal Oswal Securities Limited, Nirmal Bang Securities Pvt. Ltd., Patel Wealth Advisors Pvt. Limited, Prabhudas Lilladhar Pvt. Limited, Pravin Ratni Share & Stock Brokers Limited, RR Equity Brokers Limited, SBIcap Securities Limited, Sharekhani Limited, SMC Global Securities Limited, Tanna Financial Services, Way2Wealth Brokers Private Limited, YES Securities (India) Limited

**Escrow Collection Bank, Refund Bank and Public Offer Account Bank: HDFC Bank Limited | Sponsor Bank: HDFC Bank Limited**

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: Secunderabad

Date: June 10, 2021

KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with the Registrar of Companies, Telangana at Secunderabad. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. Kotak Mahindra Capital Company Limited, Axis Capital Limited, Credit Suisse Securities (India) Private Limited and IIFL Securities Limited at www.investmentbank.kotak.com, www.axiscapital.co.in, https://www.credit-suisse.com/in/en/investment-banking/regional-presence/asia-pacific/india/ipo.html and www.iiflcap.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" on page 28 of the RHP. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision.

This advertisement is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Krishna Institute of Medical Sciences Limited does not intend to register any part of the proposed offering of securities in the United States or to conduct a public offering of securities in the United States.

For KRISHNA INSTITUTE OF MEDICAL SCIENCES LIMITED

On behalf of the Board of Directors

Sd/-

Company Secretary and Compliance Officer